157 related articles for article (PubMed ID: 8048432)
21. Implementation of the Anemia Guidelines.
DeOreo PB; Eschbach JW
Adv Ren Replace Ther; 1999 Jan; 6(1):18-27. PubMed ID: 9925146
[TBL] [Abstract][Full Text] [Related]
22. Impact of the change in CMS billing rules for erythropoietin on hemoglobin outcomes in dialysis patients.
Ofsthun NJ; Lazarus JM
Blood Purif; 2007; 25(1):31-5. PubMed ID: 17170534
[TBL] [Abstract][Full Text] [Related]
23. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
[TBL] [Abstract][Full Text] [Related]
24. Trends in anemia at initiation of dialysis in the United States.
Obrador GT; Roberts T; St Peter WL; Frazier E; Pereira BJ; Collins AJ
Kidney Int; 2001 Nov; 60(5):1875-84. PubMed ID: 11703606
[TBL] [Abstract][Full Text] [Related]
25. Measuring, managing, and improving the quality of end-stage renal disease care.
Levinsky NG; Mesler DE
Am J Kidney Dis; 1994 Aug; 24(2):235-46. PubMed ID: 8048431
[TBL] [Abstract][Full Text] [Related]
26. Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval.
Powe NR; Griffiths RI; de Lissovoy G; Anderson GF; Watson AJ; Greer JW; Herbert RJ; Eggers PW; Milam RA; Whelton PK
JAMA; 1992 Sep; 268(11):1434-40. PubMed ID: 1512912
[TBL] [Abstract][Full Text] [Related]
27. A quarter century of medicare expenditures for ESRD.
Eggers PW
Semin Nephrol; 2000 Nov; 20(6):516-22. PubMed ID: 11111852
[TBL] [Abstract][Full Text] [Related]
28. Health Care Quality Improvement Program: a new approach.
Gagel BJ
Health Care Financ Rev; 1995; 16(4):15-23. PubMed ID: 10151886
[TBL] [Abstract][Full Text] [Related]
29. Erythropoietin claims monitoring policy: implications for clinical practice.
Messana T
Nephrol Nurs J; 2006; 33(2):209-13, 222; quiz 214-5. PubMed ID: 16613415
[TBL] [Abstract][Full Text] [Related]
30. Financing of end-stage renal disease care: past, present, and future.
Farley DO
Adv Ren Replace Ther; 1994 Apr; 1(1):24-31. PubMed ID: 7641085
[TBL] [Abstract][Full Text] [Related]
31. Improving the care of ESRD patients: a success story.
McClellan WM; Frankenfield DL; Frederick PR; Helgerson SD; Wish JB; Sugarman JR
Health Care Financ Rev; 2003; 24(4):89-100. PubMed ID: 14628402
[TBL] [Abstract][Full Text] [Related]
32. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis.
Thamer M; Zhang Y; Kaufman J; Cotter D; Dong F; Hernán MA
JAMA; 2007 Apr; 297(15):1667-74. PubMed ID: 17440144
[TBL] [Abstract][Full Text] [Related]
33. The relationship of provider organizational status and erythropoietin dosing in end stage renal disease patients.
de Lissovoy G; Powe NR; Griffiths RI; Watson AJ; Anderson GF; Greer JW; Herbert RJ; Eggers PW; Milam RA; Whelton PK
Med Care; 1994 Feb; 32(2):130-40. PubMed ID: 8302105
[TBL] [Abstract][Full Text] [Related]
34. Changes in dialysis units' quality improvement practices from 1994 to 1996.
Frederick PR; Frankenfield DL; Biddle MG; Sims TW
ANNA J; 1998 Oct; 25(5):469-78. PubMed ID: 9887699
[TBL] [Abstract][Full Text] [Related]
35. Anemia management in chronic kidney disease.
Fishbane S; Nissenson AR
Kidney Int Suppl; 2010 Aug; (117):S3-9. PubMed ID: 20671741
[TBL] [Abstract][Full Text] [Related]
36. What is expected of a medical director in the Centers for Medicare and Medicaid Services Conditions of Coverage?
Wish JB
Blood Purif; 2011; 31(1-3):61-5. PubMed ID: 21228568
[TBL] [Abstract][Full Text] [Related]
37. Legislative update ... quality of care under the Medicare program.
Roper WL
Health Care Financ Rev; 1986; 8(1):87-91. PubMed ID: 10311781
[TBL] [Abstract][Full Text] [Related]
38. Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted model.
Messana JM; Chuang CC; Turenne M; Wheeler J; Turner J; Sleeman K; Tedeschi P; Hirth R
Am J Kidney Dis; 2009 Mar; 53(3):503-12. PubMed ID: 19185402
[TBL] [Abstract][Full Text] [Related]
39. Trends in use, cost, and outcomes of human recombinant erythropoietin, 1989-98.
Greer JW; Milam RA; Eggers PW
Health Care Financ Rev; 1999; 20(3):55-62. PubMed ID: 10558020
[TBL] [Abstract][Full Text] [Related]
40. Dialysis dose, membrane type, and anemia control.
Young EW
Am J Kidney Dis; 1998 Dec; 32(6 Suppl 4):S157-60. PubMed ID: 9892384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
